Effect of Rosuvastatin on Endothelial Function

University of Hawaii

Status and phase

Terminated

Phase 3

Phase 2

Conditions

HIV Infections

Cardiovascular Disease

Treatments

Drug: rosuvastatin

Study type

Interventional

Funder types

Other

Identifiers

NCT00986999

H002

R01HL095135 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Rosuvastatin belongs to a class of medications commonly called "statins" which are medications given for high low density lipoprotein (LDL) 'bad' cholesterol to prevent atherosclerosis (hardening of blood vessels) and lower risk of heart attacks and other circulation problems. Recent studies in the general non-HIV infected population have shown that the beneficial effect of statins in preventing circulation problems is larger than would be expected from lowering of LDL-cholesterol alone. It has been suggested that the additional beneficial effect of statins may be due to the anti-inflammatory effect of statins.

The risk of heart attacks and other circulation problems may be high in HIV infected individuals. This may be due to the inflammatory stress effects of HIV. The main purpose of the study is to see if rosuvastatin will have a beneficial effect on the circulatory system in HIV infected individuals even in those who do not have high LDL cholesterol levels. Therefore, in HIV-infected individuals with normal or low LDL cholesterol levels but with evidence of low HDL cholesterol levels which may be a sign of low grade inflammation, the study will look at whether 3 months of rosuvastatin will lead to improvement in brachial artery flow-mediated dilatation (FMD), a marker of early atherosclerosis (hardening of the blood vessels).

Enrollment

7 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

HIV infection
Age > 18 years old
On stable antiretroviral therapy for > 6 months with no plans to change therapy during the treatment phase of the study
Plasma HIV RNA < 50 copies/mL
Karnofsky performance score > 70 within 30 days prior to study entry
Ability to understand and sign informed consent
Following laboratory values obtained within 30 days prior to randomization:
- Absolute neutrophil count (ANC) > 750/mm3
- Hemoglobin >/= 8.0 g/dL
- Platelets >/= 50,000/mm3
- ALT (SGPT) and AST (SGOT) < 2.5 x ULN
- Fasting glucose < 126 mg/dL
- TSH < 3.0 mIU/L
HDL-C < 50 mg/dL in men, < 55 mg/dL in women
Direct LDL-C </= 130 mg/dL
Calculated creatinine clearance > 50 mL/min
Willing to be treated with rosuvastatin or be on an observational arm for a minimum of 3 months
Female subject must not participate in a conception process (active attempt to become pregnant) or be post-menopausal. If participating in sexual activity that could lead to pregnancy, the subject must use contraception while receiving study medication and 30 days after stopping the medication

Exclusion criteria

History of past cardiovascular event
Acute illnesses or active AIDS-defining opportunistic infection (OI) within 30 days prior to entry
Other chronic illness including diabetes, autoimmune diseases, and endocrinopathies
Serology positive for hepatitis B surface antigen or hepatitis C antibody
Signs and symptoms of liver failure
Receipt of supraphysiologic glucocorticoid therapy within 3 months prior to study entry
Use of lipid lowering agents within 30 days prior to study entry
Receipt of an HIV vaccine or investigational agents
Pregnancy or breast-feeding
Presence of any active malignancy within the last 5 years
Severe Hypertension (Systolic >/= 180 or Diastolic >/= 110 mm Hg)
Use of oral postmenopausal hormone replacement therapy
Known hypersensitivity to rosuvastatin
Active drug or alcohol dependence
Any acute illness within 30 days prior to study entry that, in the opinion of the site investigator, would interfere with participation in the study.
Use of lopinavir/ritonavir (Kaletra) as part of current HIV antiretroviral regimen